独家直击！曹保平新作《涉过愤怒的海》曝“恶童”预告：直面人性幽暗 探索成长困境

曹保平新作《涉过愤怒的海》曝“恶童”预告：直面人性幽暗 探索成长困境

北京 - 由著名导演曹保平执导的电影《涉过愤怒的海》今日发布“恶童”预告片，影片将于11月11日全国上映。预告片以阴暗的色调和压抑的氛围，展现了一群“恶童”的残酷生活，引发观众强烈共鸣。

直面人性幽暗 揭露社会现实

《涉过愤怒的海》改编自同名小说，讲述了一群生活在底层社会边缘的少年，在残酷的现实环境中挣扎求生的故事。预告片中，一群衣衫褴褛、眼神冷漠的少年，在破败的街巷中游荡，他们偷窃、勒索、打架斗殴，无所恶不作。他们的行为令人憎恶，却也让人心生怜悯。

曹保平导演一直以擅长刻画人性幽暗而闻名。《涉过愤怒的海》延续了他的风格，将镜头对准了社会底层的小人物，展现了他们生存的艰难和挣扎。预告片中，有少年被警察追赶，也有少年被同伴欺凌，还有少年在绝望中呐喊。这些画面让人感到压抑和窒息，同时也引发了观众对社会现实的思考。

探索成长困境 引发共鸣

《涉过愤怒的海》不仅仅是一部揭露社会现实的电影，也是一部探讨成长困境的电影。预告片中，少年们在残酷的环境中逐渐迷失自我，他们渴望被理解、被爱护，却始终无法找到正确的方向。他们的故事引发了观众的共鸣，特别是那些曾经经历过迷茫和困惑的观众。

《涉过愤怒的海》将于11月11日全国上映，这部直面人性幽暗、探索成长困境的电影，值得所有观众观看。

以下为《涉过愤怒的海》相关信息：

• 片名：《涉过愤怒的海》
• 导演：曹保平
• 主演：范丞丞、王圣迪、冯绍峰、黄渤、陈瑾
• 上映日期：2023年11月11日

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.